|Mr. Tien Hsiang Chau||Chief Financial Officer||123.61k||N/A||1970|
|Mr. Wai Hong Chung||COO & Chief Strategy Officer||245.64k||N/A||1977|
|Dr. Yi-Chung Chao Ph.D.||Chief Medical Officer & Director||249.74k||N/A||1964|
|Mr. Yat-Gai Au||Founder, Chairman & CEO||N/A||N/A||1973|
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Regencell Bioscience Holdings Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.